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Abstract 
Objectives: To compare the occurrence of depression, anxiety, self body image perception, sleep disturbances, and diminished 
quality of life in prostate cancer patients undergoing adjuvant androgen-deprivation therapy (ADT) as opposed to patients in follow-
up alone. 
Methods and materials: Hospital Anxiety and Depression Scale, Pittsburgh Sleep Quality Index, Restless Legs Syndrome Study 
Group essential diagnostic criteria, Body Image Scale and Functional Assessment of Cancer Therapy Prostate were administered to 
consecutive prostate cancer patients who underwent radical prostatectomy or radiation therapy and are presently either under 
adjuvant ADT or included in a follow-up program. 
Results: Of the 103 patients enrolled, 49 (47.6%) were receiving adjuvant ADT and 54 (52.4%) were not. Compared with the 
controls, the patients undergoing ADT showed higher levels of depression (P= 0.002), worse self body image perception (P = 
0.001), worse quality of life (P = 0.0001) and worse sleep quality (P = 0.04). ADT was significantly associated with depression at 
multivariate analysis after adjustment for age, stage, Gleason score, as well as demographic and social variables (P=_ 0.001). 
Depression scores showed a strong inverse correlation with quality of life scores (P = 0.01). 
Conclusions: Adjuvant ADT is associated with depression, worse quality of life, and altered self body image in prostate cancer 
patients. 
 
1. Introduction 
Androgen-deprivation therapy (ADT) is the mainstay of treatment for prostate cancer patients with metastatic disease 
[1]. In prospective randomized clinical trials, ADT was found to be effective in reducing the risk of recurrence in 
high-risk men undergoing radical prostatectomy [2] and in improving overall survival in high-risk men after radiation 
therapy [3]. Although increasingly prescribed in apparently healthy men with a long life expectancy, the potential 
benefits of ADT still need to be carefully weighed against the risks of long-term toxicity. 
Several studies have shown that ADT has long-term side effects, including cardiovascular diseases, diabetes, anemia, 
bone fractures, obesity, metabolic syndrome, and decreased lean body-mass [4], all of which can diminish quality of life 
[5–7]. Furthermore, ADT can also have neuropsychiatric effects including depression. 
Low testosterone levels may, in fact, alter serotonin neurotransmission [8], negatively affecting mood as demonstrated 
in animal models [9]. Also, testosterone deficiency may decrease cerebral perfusion in the brain regions 
involved in memory, reasoning, judgment, and emotions [10], leading to a deterioration in mental and overall wellbeing 
[11,12]. Studies in elderly subjects and non-cancer patients have reported a clear association between testosterone levels 
and depressive symptoms [13]: lower testosterone levels in older men have been associated with more depressive 
symptoms [14,15], which seem to disappear with testosterone hormone treatment [16,17]. Besides contributing to the 
onset of depressive disorders, decreased testosterone blood levels can cause breast tenderness and loss of penile length 
or volume. These changes, together with unwanted weight gain, lead to a worsening of self body image perception [18]. 
Low circulating testosterone levels are associated with diminished sleep efficiency and fewer rapid eye movement 
(REM) sleep episodes with altered REM sleep latency [19]. In a large study on prostate cancer patients treated with 
radical prostatectomy, androgen blockade-related symptoms were associated with a significantly higher likelihood of 
insomnia syndrome [20]. As insomnia and worsened body image perception are both notoriously linked to depression 
[21–24], they can concur in the development of depressive symptoms associated with low testosterone levels. 
These premises notwithstanding, study results on depression in prostate cancer patients undergoing ADT remain 
controversial: one pilot study found major depressive disorder in a high percent of prostate cancer patients under ADT 
[25], whereas a large population-based analysis of depressive and cognitive symptoms in patients with prostate cancer 
failed to show a higher prevalence of depressive symptoms in ADT treated patients vs. non-treated patients after 
adjusting for age, comorbidities, and disease stage [26]. 
The present study was designed to investigate the frequency of depression and other contributory physical and 
psychological distresses, such as quality of life deterioration, worsening of self body image perception, and sleep 
disorders, in a group of consecutive prostate cancer patients referred for ADT as adjuvant therapy after loco-regional 
treatment as compared with a group of prostate cancer patients referred for follow up only. 
 
2. Material and methods 
 
2.1. Subjects 
From March to May 2007, consecutive patients either under adjuvant ADT or included in a follow-up program 
after loco-regional treatment of localized prostate cancer were recruited at the Prostate Cancer Unit, San Luigi Hospital, 
Orbassano, Italy.  
Eligibility criteria were: (1) histologically confirmed diagnosis of prostate cancer; (2) previous loco-regional treatment 
of primary tumor (prostatectomy or 3D conformational radiotherapy); (3) absence of metastatic disease; (4) at 
least 6 months follow-up after primary treatments; (5) ability to do physical and psychological tests; (6) absence of 
major comorbidities; (7) performance status 0 or 1 (Eastern Cooperative Oncology Group [ECOG] scale); (8) written 
informed consent. To be included in the study, ADT-treated patients had to have serum testosterone levels _ 0.5 ng/ml. 
Exclusion criteria were: (1) a past history of neuropsychiatric disease or consumption of anxiolytics, antidepressants, 
or other psychotropic drugs before the diagnosis of prostate cancer; (2) progressive disease, defined as an increase 
in serum prostate-specific antigen (PSA) levels at 2 consecutive assessments and/or new lesions in bone, viscera, 
or lymph nodes detected at study entry. The study protocol was approved by the local Ethical Committee, and written 
informed consent was obtained from all patients before entry into the study. 
The patients were divided into 2 groups according to whether they received adjuvant hormone treatment or not. 
Patients with low or intermediate risk according to National Comprehensive Cancer Network (NCCN) guidelines 
criteria [27] who had undergone radical prostatectomy were referred for follow-up alone. Adjuvant hormone therapy 
was recommended to all patients who had received radiation therapy and to high-risk patients undergoing radical 
prostatectomy. 
ADT consisted of 11.25 mg LHRH-A alone, given subcutaneously or intramuscularly every 3 months. Antiandrogens 
(bicalutamide or flutamide) were added to the LHRH-A regimen during the first month of therapy to prevent tumor 
flare. 
 
2.2. Assessment instruments 
In order to integrate both clinical and psychological assessment at the onco-urologic follow-up visit, the data were 
collected using question-based interviews conducted by 2 research assistants, 1 from the nursing staff and the 
other from the clinical psychology group. The first section of the 2-part questionnaire was composed of general 
questions about gender, age, education level, civil status, place of residence (i.e., urban, suburban, rural), and time since 
the start of anticancer therapy. 
The second section consisted of: Functional Assessment of Cancer Therapy-Prostate (FACT-P): a multidimensional, 
self-report instrument for quality of live (QoL) assessment, specifically designed for use with prostate cancer patients. It 
consists of 27 core items that assess patient function in four domains: physical, social/ family, emotional, and functional 
well-being; it is further supplemented by 12 site-specific items that assess for prostate-related symptoms (Prostate 
Cancer Scale). Each item is rated on a 0 to 4 Likert-type scale, and then combined to produce subscale scores for each 
domain, as well as a global QoL score. Higher scores reflect better QoL [28]. Internal consistency as measured by 
Cronbach’s _ was at least 0.84 for all 5 subscales. Hospital Anxiety and Depression Scale (HADS): this tool measures 
levels of anxiety and depression and investigates for the presence of mood disorder in hospital populations and hospital 
outpatients [29]. It consists of 2 subscales that measure anxiety and depression status separately. Each subscale contains 
7 items, rated on a 4-point (0 –3) scale, which are then added to produce a score from 0 to 21 for both anxiety and 
depression. For each subscale, a score of 0 to 7 indicates a normal condition; 8 to 10 is suggestive of anxiety or 
depression; 11 or higher indicates the probable presence of mood disorder. Internal consistency as measured 
by Cronbach’s _ was 0.78 and 0.73, respectively. 
Body Image Scale (BIS): this 10-item assessment instrument designed for use with cancer patients [30] measures 
the impact of medical and surgical treatments on self-consciousness, physical and sexual attractiveness, masculinity, 
satisfaction with body and scars, body integrity, and avoidance behavior. Each of the 10 BIS items are scored from 0 
(not at all), through 1 (a little), 2 (moderately), to 3 (very much), giving a summary score range of 0–30. Higher 
scores denote increased negative change or dissatisfaction with body image. The BIS was employed to evaluate the 
impact of hormone therapy on self body perception. Internal consistency as measured by Cronbach’s _ was 0.77. 
Pittsburgh Sleep Quality Index (PSQI): this tool measures subjective sleep quality in the preceding 1-month 
period and consists of 19 self-rated questions and 5 questions rated by a bedpartner or roommate. The 19 items are 
grouped into 7 component scores: sleep quality, sleep latency, sleep duration, sleep efficiency, sleep disturbances, 
use of sleep medication, and daytime dysfunction. The global PSQI score (range 0–21) is calculated by summing 
the component scores, whereby a higher score indicates worse sleep condition. A global PSQI _ 5 has been suggested 
to distinguish poor (PSQI _ 5) from good sleepers (PSQI _ 5), with diagnostic sensitivity of 89.6% and specificity 
of 86.5% [31]. Internal consistency as measured by Cronbach’s _ was 0.83. The Italian versions of the assessment 
instruments are currently employed in clinical trials (FACT-P), as well as in daily practice of psychiatry/clinical 
psychology and sleep disorder centers. 
 
2.3. Statistical analysis 
The internal consistency reliability of each scale was calculated using Cronbach’s _ and the 0.70 standard for 
group-level comparisons was adopted [32]. According to the Kolmogorov-Smirnov test, a non-normal distribution 
was observed for BIS (P _ 0.002), while FACT-P, HADS, and PSQI were normally distributed. 
Differences between continuous variables were assessed by the Mann-Whitney U test for nonparametric data or the 
t-test for parametric data when indicated. _2 or _2 for trend tests were used to compare categorical variables. The 
Spearman test for nonparametric data or the Pearson test for parametric data were used when indicated to calculate 
correlations between variables. Multivariate logistic regression was employed to identify independent variables 
associated with depression. In the logistic regression model, a HADS score of 7 was set as the cut-off value for 
depression (dependent variable) to discriminate between nondepressive and depressive patients. Among the independent 
variables, age was considered as a continuous variable, while serum PSA, Gleason score, stage, occupation, living 
alone, civil status, and education were categorized as described in Table 1. Multivariate logistic regression was also 
employed to identify independent psychological variables associated with ADT. All statistical tests were two-sided; 
statistical significance was set at P _ 0.05. Statistical computations were performed using SPSS ver. 16.0 for Windows 
software (SPSS Inc., Chicago, IL). 
 
3. Results 
 
3.1. Patient characteristics 
The study population was 103 patients, 49 (47.6%) of whom had undergone hormone therapy with LH-RH analogues 
and 54 (52.4%) had not (control group). The control group included 47 low-risk and 2 high-risk patients who had 
undergone radical prostatectomy and 5 low-risk patients treated with radiation therapy, who declined the recommended 
hormone therapy due to fear of impotence. 
Table 1 summarizes the patient characteristics. The patients referred for adjuvant hormone therapy were slightly 
older, with a more advanced disease stage and higher Gleason scores and PSA levels than the controls. They were 
more frequently treated with radiation therapy rather than radical prostatectomy as primary loco-regional therapy. No 
differences between the 2 groups were observed for occupation, living alone, civil status, education, and time since 
diagnosis. 
 
3.2. Relationship between depression and other variables 
A strong direct correlation emerged between depression score and total FACT-P score (Pearson r 0.61; P = 0.01), 
with anxiety (Pearson r 0.71; P = 0.0001), and total PSQI score (Pearson r 0.79; P = 0.0001). Conversely, a weak 
direct correlation was found between depression and BIS score (Spearman r 0.21; P = 0.03). At multivariate regression 
analysis, however, only FACT-P and anxiety were independently associated with depression (P = 0.003 and 
P = 0.0001, respectively), whereas BIS and PSQI were not (P = 0.07 and P = 0.52, respectively). 
 
3.3. Anxiety and depression 
No differences in anxiety levels between the two groups were observed, whereas the patients receiving hormone therapy 
were noted to have more severe depression (P = 0.002) (Table 2): 44 (81.5%) patients in the control group had no 
depression (HADS score = 7) vs. 26 (53.1%) in the ADTtreated group; 6 (11.1%) had moderate depression (HADS 
score 8–11) vs. 13 (26.5%) in the ADT-treated group; and 4 (7.4%) had severe depression (HADS score = 12) vs. 10 
(20.4%) in the ADT-treated group (=2 for trend; P = 0.004). Hormone therapy was significantly associated with 
depression at multivariate analysis after adjustment for age, stage, Gleason score, as well as demographic and social 
variables (relative risk, 5.56; 95% confidence interval [CI], 2.10 –14.8; P = 0.001) (Table 3). Only age had an 
independent predictive role of borderline significance. 
 
3.4. Quality of life 
Table 2 presents the FACT-P subscale scores of the ADT-treated patients and the controls. The total FACT-P 
score was significantly lower (P = 0.001) in the ADT-treated patients than in the controls, as were the subscale 
scores for physical well-being (P = 0.001), social/family well-being (P = 0.009) and functional well-being (P = 
0.0001). The scores for emotional well-being and prostate cancer subscale were fairly similar in both groups. 
 
3.5. Body image scale and sleep disturbance 
Table 4 and Table 5 present the scores on the Body image scale and PSQI components, respectively. The total 
BIS score was consistently higher in the ADT-treated patients than in the controls (P = 0.001), indicating worse 
self-image perception. Significant differences were observed in all single items, except for self-consciousness of 
appearance and satisfaction with appearance when dressed, on which the ADT-treated patients scored significantly 
higher. 
No statistically significant difference emerged between the 2 groups for total PSQI and relevant items, except for the 
daytime dysfunction (P = 0.03) and the sleep quality components (borderline significance; P = 0.07), which were worse 
in the ADT-treated patients than the controls. 
 
3.6. Psychological distresses independently associated with ADT 
Since most psychological scales were associated with depression, a multivariate logistic analysis was performed 
to assess whether these variables were independently associated with ADT. As outlined in Table 6, all the variables 
except PSQI were independently associated with ADT. 
 
 
4. Discussion 
 
Androgen-deprivation therapy is increasingly administered for early stages of prostate cancer, exposing men to 
prolonged periods of treatment. In light of these trends, concerns have been raised about the toxic effects of ADT. 
Physicians are aware of the metabolic and physical toxicity of ADT, but relatively scarce attention has been paid to its 
psychological side effects. Both hypogonadism and testosterone deprivation have been associated with depressive 
disorders in non-neoplastic men [13–15]. The correlation of depression with ADT in prostate cancer patients, however, 
is more difficult to demonstrate because many depressive effects could plausibly occur secondary to a diagnosis of 
cancer and the onset of relevant symptoms. In a large-scale series of patients in the linked Surveillance, Epidemiology, 
and End Results–Medicare database [26] involving either metastatic or apparently disease-free patients, the risk of 
depression associated with androgen deprivation was substantially abolished after adjustment for variables such as 
comorbidity, tumor characteristics, and age. In the present study, we evaluated depression and other physical and 
psychological distresses contributory to depression in a consecutive series of patients who had received loco-regional 
treatments (radical prostatectomy and radiation therapy) for non-metastatic disease, 48% of whom were receiving ADT 
and 52% were under follow-up alone. Patients with major comorbidities were excluded from the study to minimize 
biases. Our ADT-treated patients were slightly older than the controls and, as expected, had a more advanced tumor 
stage and grade, and were more frequently referred for radiation therapy than prostatectomy as primary 
local treatment. The 2 groups were well-matched for civil and social status. 
Depression strongly correlated with poor quality of life, anxiety, and sleep disorders, substantially confirming previous 
findings [5,6,23,24,33]. The weak relationship between depression and changes in self body image perception 
suggests that this distress may be scarcely associated with the depressive symptoms. 
The main finding of our study is that depressive symptoms were more frequently observed among the ADTtreated 
patients. ADT was also strongly associated with diminished quality of life (particularly in the domains of physical well-
being, social/family well-being, and functional well-being) and worsening in self body image perception. 
Sleep disorders were only marginally affected, whereas no effect on anxiety was observed. Since depression, quality of 
life and, to a lesser extent, self body image perception were reciprocally correlated, an interesting issue is whether the 
depressive symptoms in our series were associated directly with testosterone deficiency or indirectly as a consequence 
of fatigue, physical impairment, and changes in body image related to ADT [34,35]. A multivariate logistic regression 
analysis showed that depression was independently associated with ADT and this suggests a direct effect of treatment. 
The cross-sectional nature of the study did not allow us to discriminate whether the increased frequency of depression 
among the ADT-treated patients was due to the treatment received or was already present before treatment began. As 
the 2 populations significantly differed in prognostic factors at baseline condition, this could potentially have 
contributed to the difference in the occurrence of depression between the groups. It should be noted, however, that the 2 
groups had been similarly informed by the physicians about the prospects of disease outcome and that the greater 
frequency of depression among the ADT-treated patients persisted at multivariate analysis after adjusting for age, stage, 
Gleason score, as well as demographic and social variables. These observations notwithstanding, the absence of an 
evaluation of depressive disorders at baseline condition is admittedly the main limitation of the present study. 
The multivariate logistic analysis of psychological variables independently associated with ADT, points out that 
anxiety has a statistically significant inverse correlation with ADT, thus patients submitted to hormone therapy are less 
likely to have anxiety than those non submitted. Since anxiety and depression are frequently directly correlated, it 
is difficult to explain this apparently counter-intuitive finding. 
It could be hypothesized that men on ADT may be somewhat reassured of being under antineoplastic treatment, 
while those in follow-up only could be more afraid of a tumor recurrence. This hypothesis needs confirmation in a 
prospective trial. Depression is notoriously linked to sleep disorders [24], and the strong correlation that emerged 
between depression and PSQI scores confirms this observation. The interplay of cause and effect has attracted 
increasing attention, though the underlying pathophysiology remains unclear [36]. Vasomotor symptoms are known to 
be strong predictors of trouble sleeping [37], which might have been responsible for the insomnia syndrome in our 
series. Unfortunately, the frequency of hot flushes was not recorded in our series, and this is a further limitation of the 
present study. ADT, however, was noted to have only a slight effect on sleep disturbances in our series. The relationship 
between testosterone and sleep disorders is very complex, and the interaction between the 2 is probably bidirectional, as 
recently reviewed [19]. A high incidence of insomnia has been observed in men undergoing radical prostatectomy 
even in the absence of ADT [20], which may explain, at least in part, the lack of a strong effect of ADT on sleep 
disorders in our series. Epidemiologic data indicate an association between major depressive disorder and increased 
cardiovascular morbidity and mortality [38,39], suggesting that depression can account, at least in part, for the increased 
cardiovascular morbidity of ADT [39,40]. 
The inclusion of a rather homogeneous population of non-metastatic prostate cancer patients and the ability to adjust for 
potential confounders are the strengths of this study. However, it also has several limitations. As mentioned, it was 
cross-sectional in design and episodes of hot flushes were not recorded. In addition, serum testosterone was not 
measured in the controls and was inhibited in the ADT group, so that we were unable to test for correlations between 
serum testosterone and depression. Moreover, the lack of a follow-up evaluation did not allow us to determine whether 
the psychosocial findings were related to the adjustment process, which usually normalizes within a few months, or 
were due to more lasting mental disorders. 
 
5. Conclusion 
 
The present study provides evidence that ADT is associated with depression, worsening in quality of life and altered 
body image perception, and sleep disturbances. These results extend the impact of ADT into the psychological domain 
beyond the already available data on its metabolic and physical toxicity, and reinforce the notion that prescribing ADT 
in apparently healthy men with a longer life expectancy needs to be carefully weighed against the risks of its long-term 
side effects. 
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